In short
Episode about: A CNBC Squawk Pod segment covering market moves and geopolitical risk (U.S. seizure of an Iranian ship near the Strait of Hormuz; debate over whether the UAE might seek U.S. help/currency support), plus three major “future” themes: (1) private credit liquidity problems and how to think about valuation and investor suitability, (2) AI-driven labor disruption and Fed Chair nominee Kevin Warsh’s tech ties and views, and (3) medical innovation—Eli Lilly’s CAR-T expansion and psychedelics regulation under an executive order.
Guests (backgrounds)
Howard Marks (Oaktree Capital co-chairman; alternative investments; ~$223B AUM); Dr. Scott Gottlieb (former FDA Commissioner; board member at Pfizer and Illumina); Steve Leisman (CNBC senior economics reporter interviewing on Warsh).
Key claims
Private credit isn’t inherently bad; problems come from overdone lending, rushed capital, and mis-selling to investors who can’t tolerate illiquidity; private valuations lack clear market reference points. Warsh argues central bankers must “front run” AI productivity impacts; AI could cause 20–30% unemployment. Gottlieb says in vivo CAR-T and mRNA “cancer vaccines” personalize immune targeting; psychedelics policy should expedite FDA/DEA pathways while keeping trials supervised.
Notable examples
In vivo CAR-T vs extracted-cell CAR-T; CAR-T for multiple myeloma; mRNA tumor-antigen approach with long survival in early pancreatic cancer trials; ibogaine for veterans; NSA use of Anthropic’s “Mythos” AI; QXO buying TopBuild; prediction markets framed as entertainment/casino.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOMarket Movements Recap
0:00 to 0:24
Analysis of significant movements in the stock market.
“Bring it all together with EverPure, the platform that acts like a living system, delivering the latest in data performance, security, and innovation without ever slowing you down.”
Market Movements Recap
0:33 to 0:57
Analysis of significant movements in the stock market.
“including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading.”
Market Movements Recap
1:26 to 1:59
Analysis of significant movements in the stock market.
“Like any casino, it's not a fundamental bet.”
U.S.-Iran Tensions Discussed
1:59 to 4:10
Discussion on the ongoing tensions between the U.S. and Iran.
“Even though the government has named it a risk.”
Economic Impact of Iranian Conflict
4:10 to 6:10
Exploring the economic ramifications of U.S.-Iran tensions.
“President Trump said on Sunday afternoon that a 900-foot-long Iranian-flagged cargo ship attempted to run the U.S.”
Corporations and Market Reactions
6:10 to 8:10
Discussion on corporate reactions and market implications of geopolitical events.
“Yeah, well, I mean, what you're seeing now is economies under stress throughout the region.”
AI in Government Use
8:10 to 10:34
Insights on the use of AI technology by the U.S. government.
“Construction supplies distributor QXO is buying insulation installer and distributor top build.”
Upcoming Fed Chair Confirmation Hearing
10:34 to 13:38
Preview of Kevin Warsh's upcoming confirmation hearing for Fed chair.
“Axios reported that Wiles made clear the government needs a relationship with Anthropics.”
Warsh's Background in Tech
13:40 to 14:00
Examination of Kevin Warsh's connections to the tech industry.
“Download the latest episode and subscribe at schwab.com slash market update podcast or find Schwab Market Update wherever you get your podcasts.”
Kevin Warsh's Tech Connections
14:15 to 15:40
Discussion on Kevin Warsh's ties to technology and potential impact on the Fed.
“Kevin Warsh, President Trump's nominee for Fed chair, is set to be grilled tomorrow at his confirmation hearing before the Senate Banking Committee.”
Show all 21 chapters
The AI and Unemployment Debate
15:40 to 18:08
Exploration of AI's potential effects on unemployment and productivity.
“There's one at least at San Francisco's airport.”
Universal Basic Income Controversy
18:08 to 20:24
Debate over universal basic income in the context of rising unemployment.
“And is that a forever thing or do we figure out how to re-employment?”
Private Credit Concerns
20:24 to 22:32
Discussion on the challenges and issues facing private credit markets.
“My point is that I imagine when we get to a UBI debate that you and I.”
Valuation Difficulties in Private Equity
22:32 to 28:00
Insights into the complexities of valuing private companies and assets.
“I need to report that story because what you're talking about, the swap line, that's a Fed thing.”
Market Dynamics and AI Influence
28:00 to 33:56
Explore the ongoing tension between optimists and pessimists in the market, especially related to AI stocks.
“You know, every day there's a tug of war in the market between the optimist and the pessimist.”
Private Credit Concerns
33:56 to 36:23
Discuss the implications of private credit and equity products for retirement plans and their suitability.
“whether you think those plans should be in 401k plans.”
Investor Psychology and Market Timing
36:23 to 38:47
Analyze how human emotions influence investment decisions and market behavior.
“I mean, some of the vintages more recently have actually underperformed.”
Innovations in CAR-T Therapies
39:00 to 42:02
Delve into the advancements in CAR-T therapies and their impact on cancer treatment.
“That was something that veterans wanted a sort of rational development process around.”
Advancements in CAR T Therapy and mRNA Vaccines
42:02 to 44:40
Learn about new CAR T therapies and mRNA vaccine developments in cancer treatment.
“or a lipid nanoparticle that also does the same thing.”
President's Executive Order on Psychedelics
44:42 to 46:54
Explore the implications of the president's executive order on psychedelics for mental health treatment.
“This was to approve or to go after psychedelics.”
FDA Approval Challenges and Drug Development
46:55 to 49:42
Understand the challenges faced by pharmaceutical companies in drug approvals and FDA interactions.
“One of the challenges to doing clinical trials here is you get functional unblinding.”
Transcript
Automatic transcript. May contain errors.0:00Your data lives everywhere. On-prem, in the cloud, across apps. Bring it all together with EverPure, the platform that acts like a living system, delivering the latest in data performance, security, and innovation without ever slowing you down. Sophisticated enough to anticipate your ever-changing data needs, yet simple enough to feel like second nature. Tame your data chaos with EverPure and make storage and data management the simplest part of your business. Visit everpuredata.com to learn more. This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading.
0:47Download the latest episode and subscribe at schwab.com slash marketupdatepodcast or find Schwab Market Update wherever you get your podcasts. Bring in show music, please.
1:25I want to take advantage of the mistakes that other people make. And weighing in on prediction markets. Well, it's entertainment. Like any casino, it's not a fundamental bet. Then innovation in health care. Former FDA Commissioner Dr. Scott Gottlieb on psychedelics regulation and Eli Lilly's deal to expand its cancer treatment pipeline. The technology around cancer vaccines, what people call broadly cancer vaccines, ways to try to train the immune system to recognize cancer. We've been working on these for probably three decades now. Plus. I'm thinking about AI like washing machines. AI at work even at the NSA.
2:06Anthropics in the government. Even though the government has named it a risk. It's such a joke. We just say it's such a joke. These are like talks with Iran. It's Monday, April 20th. A supersized squawk pod begins right now. Stand Becky by in three. Two, one. Cue it, please. Good morning, everybody. Welcome to Squawk Box right here on CNBC. We are live from the Nasdaq market site in Times Square. I'm Becky Quick, along with Joe Kernan and Andrew Ross Sorkin. Hello, everybody. Good to see everybody back together. Good to see you. But yeah, you go away for a week and wow, what a move in the markets.
2:43I think over the last week, the Dow was up by 3.2 percent and it was the laggard among all the rest. The S &P 500, the Nasdaq, the Dow Transports, all closing Friday at new highs. In fact, the S &P was up by 4.5 % for the week, and the Nasdaq, if you can believe it, was up by 6.8%. So some pretty massive moves that we've seen in equities. What was the building we called our brand-new CNBC headquarters in England? What was it, Dow 20 ,000? No, no. Dow 10? What was it? I can't remember. Dow 5 ,000, was it really? No, Nasdaq. I mean, Nasdaq. I'm sorry, Nasdaq 5 ,000, right? I just remember the hats.
3:19That's all I remember. The averages fell at. We built a beautiful facility out there right at the top of the NASDAQ market. And then when it fell, we always refer to it as the NASDAQ 5 ,000. Was it the NASDAQ 5 ,000? Yeah. You know what the NASDAQ is today? Do tell. Well, almost. More than. 25. 25 ,000. So that just shows you we're old and we're getting older. But that was what we were witnessing back in the early 2000s. What that tells you is invest over time because markets work. Invest in technology. If you are patient, yes. Of course, the question in the morning right now is about the state of the peace talks between the U.S.
3:58and Iran. It's been the question of the morning for some time. Markets seem to have been shrugging this off for the most part, nonetheless, following the U.S. military seizure of an Iranian ship. Let's get over to Eamon Javers in Washington, D.C. this morning. He's got the latest. Eamon. Yeah, good morning, guys. President Trump said on Sunday afternoon that a 900-foot-long Iranian-flagged cargo ship attempted to run the U.S. Navy's blockade of the Strait of Hormuz, but was intercepted by the U.S. Navy guided missile destroyer USS Spruance, which gave the Iranians a warning. The Iranian crew refused to listen, Trump wrote on social media, so our Navy ship stopped them right in their tracks by blowing a hole in the engine room.
4:40Right now, U.S. Marines have custody of the vessel. Now, CENTCOM released this video, it says, shows U.S. forces telling sailors to vacate the engine room and then firing on the ship. The U.S. said the Spruance fired rounds from its 5-inch MK-45 gun and Marines from the 31st Marine Expeditionary Unit boarded the noncompliant vessel. Now, the president also said the vessel had been under U.S. Treasury sanctions due to a prior history of illegal activity. That followed an earlier post in which the president said that Iran had fired on vessels from France and the United Kingdom. Iranian state media said late Sunday, under these conditions, the outlook for constructive talks remains bleak.
5:27And they said the reports circulating about a second round of negotiations in Islamabad are false. So it's not clear now what the status of talks is at this point. The Iranians say they're not happening. The president told MSNOW yesterday that they are happening, but that Vice President J.D. Vance would not go due to security issues. And then a U.S. official followed up to say that, yes, in fact, Vance is going, but the president hasn't directly confirmed that, guys. So that's where we are this morning. Let me ask you another question, which is there was a report in The Wall Street Journal that the UAE may be asking for assistance from the U.S.
6:05government to help potentially either bail it out or some kind of currency swap. Yeah, well, I mean, what you're seeing now is economies under stress throughout the region. Right. And I think one of the big questions in all of this has been, does this escalate to a broader Gulf calamity? And, you know, the longer this goes on, the more likely you are to get to a point where you're going to see a number of countries in significant distress because you can't put oil production and oil exports down to something just barely north of zero and not have sort of extended problems throughout all of these economies.
6:43So the question is, how does the U.S. handle the economic fallout as the Iranian side says they're waging economic war? I mean, we saw Iranian officials over the weekend like taunting the U.S. Treasury market, U.S. oil markets in social media posts. They are very much focused on the economic consequences. But can you see as their leverage here? The idea, though, that politically we would ultimately be bailing out our allies in the Middle East. How well or not do you think that would go over here? Yeah, I mean, I think, you know, domestically, not great, especially among MAGA voters. The idea of the United States bailing out these wealthy oil nations, you know, is a political, you'd have to say, close to nonstarter.
7:27That said, it is a new world, Andrew. And if you're looking at the, you know, an economic wipeout of some of these economies, you know, the game has changed. But are we talking about an economic wipeout and this idea that these these wealthy oil nations are going to need a bailout is is remarkable, if true. Yeah, well, sure. But temporarily, you'd have to imagine. Right. I mean, at some point, the war will be over. Yeah, at some point, the war will be over, and they'll have assets they can sell and transactions they can make. The question is, how long do we go between here and there? And so maybe think of it more like a sovereign bridge loan than anything else.
8:10Eamon Javers, thank you. Construction supplies distributor QXO is buying insulation installer and distributor top build. The deal values top build shares at$505 a piece. QXO says that the deal will create the second largest publicly traded buildings products distributor in North America. It also said that the deal is expected to be immediately accretive to earnings. CEO Brad Jacobs flagging data centers as one area of focus for the combined firm. And it looks like this is going to be partially in cash, partially in stock, something like 45 % in cash, 55 % in shares. They can elect to receive that in cash or 20.2 shares of QXO common shares for each top-billed share that's held.
8:59We didn't put a value on it, but if you look at the market cap of top-billed. $11.5 million. $11.5 million, plus it's up$80 a day. It's a 30 % premium, so maybe$16 billion. Yeah, pretty big. The journal led with a deal in pharmaceutical biotech with Eli Lilly. It's only$2 billion. But it's kind of interesting. I thought we had multiple myeloma pretty much under control. But the way that we do it now, you get chemo, and then you take some immune cells out and change them and put them back in. It's pretty harsh. This would do it with CAR T cells. With CAR T therapy, yeah. And you wouldn't need the chemo to start, and you wouldn't need to take the...
9:35Which would be a much better way of going through it. So, I mean, this is a very small company, but it's got a platform for multiple myeloma, which maybe, that's what I think, that maybe it's more than just for multiple myeloma. The National Security Agency is reportedly using Anthropoc's powerful new AI model, Mythos. An Axios report says that it's not clear how the agency is deploying the model, but others with access are using it to probe their own systems for security gaps. The NSA falls under the Defense Department, which last month labeled Anthropic a supply chain risk. This news follows a White House meeting on Friday between Anthropic CEO Dario Amodi and the White House Chief of Staff Susie Wiles, also Treasury Secretary Scott Besant.
10:25In a statement, Anthropic said that the meeting focused on cybersecurity and America's lead in the AI race and called the discussions productive. Axios reported that Wiles made clear the government needs a relationship with Anthropics. This is such a joke. Can we just say it's such a joke? I think it's interesting. These are like talks with Iran. But it's such a joke that, and by the way, this is going to be used in the case against the government ultimately. For the supply chain. For this ridiculous supply chain risk theory that they've tried to place against this company and now they're using it again.
11:02And when they go to court, they're going to say, hello, there's such a supply chain risk that we're using it. And you had everybody come out. You know, you had Emil come on here and tell everybody not to use it. You had Scott Besson come on here and tell everybody not to use it. And here it is. It's the best model in the country. They have to use it because it's so good. You'd want them to use it. And they were playing. But here's the most important part. They were playing politics. That's what this was always about. Knock me down with a feather. You live in this world. It should be sinking in by now that this is the way things work.
11:38But we shouldn't be happy about it. I don't know. I can't say I'm going to. I didn't think. All weekend I was grinding in, Jesus, this anthropic stuff. We don't want to lose our AI lead. I think that's pretty important. I think that's the message that comes out of it. Right. Cheese will be next. Still to come on Squawk Pod, gearing up for the confirmation hearing for President Trump's pick for next Federal Reserve Chair Kevin Warsh, and drawing workforce parallels between the age of AI and the age of automation. Nothing was more significant in terms of bringing women into the workforce like washing machines.
12:18Did we have jobs for them before? Did we invent or create jobs for their existence? Then, later, Oak Tree's Howard Marks. Emotion, what we call human nature, tends to get us excited when things go well. And as things go well, prices rise, rise, rise, and people want to buy more, more, more. You don't want to miss his take on the markets. I like to buy when things are on sale, not be coerced into selling when things are on sale.
12:52If you are hearing this, you have been chosen. Chosen by Hangry Joe's Hot Chicken. Welcome to your reprogramming. Relax and let the flavors wash over you. You are getting very, very hangry. Hangry for golden fried perfection. You are feeling warm all over. When you wake, you will understand a new reality of flavor. you will know. Hangry Joe's. Welcome to our flock. Hangry Joe's hot chicken and wings. If you know, you Joe. I'm honored to make history and to make my community proud. What a brilliant tackle from Naomi Kerma. What would you like the power to do? Bank of America. Proud to be the official bank of U.S.
13:36soccer. Bank of America N.A. member FDSE. This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com slash market update podcast or find Schwab Market Update wherever you get your podcasts.
14:11Welcome back to Squawk Pod from CNBC. Here's Becky Quick. Kevin Warsh, President Trump's nominee for Fed chair, is set to be grilled tomorrow at his confirmation hearing before the Senate Banking Committee. Our senior economics reporter Steve Leisman joins us right now with a look at Warsh's connections to technology and the tech bros, so they said. Becky, good morning. Kevin Worsh may not be a tech bro himself, but he's gone to school and invested alongside them and been steeped in tech investing for a decade and a half, making it a key part of understanding how Worsh would run the Fed and monetary policy.
14:49Worsh befriended leading tech investors Peter Thiel, Marc Andreessen, and Jerry Yang, founder of Yahoo, at Stanford in the early 90s after resigning as a Fed governor in 2011. He would later be a co-investor with many of them in a series of private and public tech companies, including Alex Karp from Palantir and David Sachs. Worsh joined the family office of Stan Druckenmiller after leaving the Fed, his longtime friendship with his techie schoolmates, along with the investment savvy and cash of Druckenmiller, opened doors in Silicon Valley. Worsh's 69-page financial disclosure document showed vast wealth, reaching at least nearly $200 million, potentially far more.
15:25There are marquee investments into Palantir, along with riskier startups ranging from crypto to artificial intelligence to this one, a company that makes a robotic barista that will automatically serve a latte, a lemonade or a premium jasmine milk tea from a booth. There's one at least at San Francisco's airport. All of this helps shape more strong optimism about the promise of tech and productivity for the U.S. economy. He said we're probably on the front end of use cases of AI before it was clear that there would be agents out there. That was in May 2025. Everything technology touches gets cheaper, he said in a separate interview, where he said central bankers need to make a bet on technology before it shows up in the data.
16:03Otherwise, they're going to be too late. Warsh looks far more likely to front run potential productivity and negative labor market impacts from AI and tech than the current share. And even many of his fellow would-be committee members. That sets up a really interesting debate between conventional and tech pro monetary policy under Warsh. Warsh. I know what you're going to ask. I got to ask him about that. Shulman at Verizon predicting unemployment of 20 to 30 percent within two to five years. Because of AI. Look, if anybody knows this is potentially coming, I think Warsh is going to be that person.
16:40The question is, how do you react to it? One of the pushbacks against this front running productivity is this notion that on the front end, And AI is essentially raises prices. It's an infrastructure investment. It's a capex investment. The productivity is down the road. And I don't know if you've noticed, but every time I've had a Fed chair on, a Fed official on, I've asked them the same question about this idea of front running. Hammock didn't like it. Goolsbee didn't like it. A lot of people are very wary about getting in front of it. And then we're like, well, let's wait until it happens. Warsh's idea is that's too late.
17:15You're already behind the curve if you wait to see it in the data. What would that mean? It would mean, I think, lower interest rates. No, 20 to 30 percent unemployment. That would be a. I can tell you what that means. I wrote a whole book about it. Twenty five percent unemployment, 1932. That was it. That was for a bad reason. This theoretically is for a good reason. But Elon Musk is on board with this universal basic income at this point, said that they should be very high income. Joe, when you lose your job, is there ever a good reason I lost my job? Oh, I'm fine because everybody else will be more productive.
17:50I don't know if that's... I'm just saying it would be seismic. It would be the worst thing. Because if you believe, like Arthur Brooks, that the value of life is in the dignity of work. Work. And 20 to 30 percent of people are unemployed. Not because of a break in the stock market, but because of structural changes in how everything works. And is that a forever thing or do we figure out how to re-employment? Can I give you my weird take on this for a second here? I don't know. Go for it. I'm thinking about AI like washing machines. If you think about washing machines and household appliances, nothing was more significant in terms of bringing women into the workforce like washing machines.
18:36All of a sudden, this vast cadre of people were available to work. But it was also processed food, the ability to get a meal on the table quickly. That was all part of it. But when you think about all of these things that all of a sudden made all of these women available to work, did we have jobs for them before? Did we invent or create jobs for their existence in the workforce or their availability to labor? The other side of people losing their job is availability of labor. and I don't know that we know what they're going to do, but if it happens quickly, it's a calamity. The only reason I'm going to push back on this...
19:18You should push back. It's a theory. It's just working on it. I think both in the services area, there's a lot of things that this can do almost autonomously on its own without much human in-the-loop relationship. And similarly, once you hit robotics, then you really change the dynamics. And then the last piece is, despite Elon Musk and maybe some others talking about UBI, universal basic income and other things, you tell me whether you really believe politically that that is going to be the path and whether there's not going to be a massive fight about whether the spoils in a capitalistic society are supposed to go ultimately to the model makers and chip manufacturers and all of those people relative to everybody else.
20:06And I think no matter how much fighting there is to try to get either UBI or some kind of redistribution going, there is going to be a very vocal group on the other side of that argument that is going to at least win some part of it, if not all of it. We need equal opportunity, not equal outcome. And egalitarian societies that are based on transfer payments are anathema to capitalism. You're right. My point is that I imagine when we get to a UBI debate that you and I. A lot of people aren't going to want it. Correct. Exactly. Because it wasn't earned. That's what they're going to say. Right. And so then you tell me how this whole society is supposed to operate.
20:45Yeah. And the idea of like what you were saying from the book when you went back to 1929 and talked about the unemployment. Are you then talking about permanent unemployment of 20 to 30 percent? I mean, that's the real question. Right. I mean, how long do you live in this? people forget there were tented camps literally across this country you go to central park by the way hooverville's i mean people were living in tents we have those all over yes but not like this at all i mean i mean think about what unemployment's like right now it's like alice in wonderland compared to what that period was ubr taxes on corporations that are going to be reaping all of this money no from firing all these people not on corporations they should keep keep making money corporations not on corporations no because you're talking share well you're also not going to shareholder it's not corporations aren't aren't people like but but if you have all the tech pros that we brought up here and they're making all their money from well then not from income but it's not income they they can it's not you can tax them but i just wouldn't tell wait how would you tax them would you tax them on their assets i do it that would do it with if they borrow money you gotta if they live off their their wealth that's a big deal here that's No, it's not.
21:57That's the Ackman-Sorkin model. I've been talking about that for years. Oh, I know, but there's a lot of... Joe's coming along, you're saying. No, I've always said that. If you want to do that, fine. You can raise, like, 1 % of what we need. I think this is a whole show someday. I mean, I think that... Look, there's a thing called Say's Law. You run out of billionaires, Steve. No, there's an economist called Say who said the demand for labor equals the supply for labor. We are so out of time, but I have one last question. This conversation, this is not a Fed thing, but a Treasury thing. This conversation apparently happening with Scott Besson and the UAE about a bailout.
22:33I need to report that story because what you're talking about, the swap line, that's a Fed thing. The Fed creates the swap line, as far as I know, unless there's some other means where Besson would use the exchange stabilization fund. I don't know to provide some assistance to UAE. I'm sorry, guys. It's not me. Well, it is me. I messed up. I'm talking to the guys in the back. I know. We're going long. But this is a big issue this morning. I need to call the Fed to see if there's some discussion. And the fact that the UAE is even having a conversation about this suggests that they might be really, I don't know, the question is how worried are they?
23:07And where are we in that? Look, it was Waller who on Friday said the market is undervaluing the impact of the straits being closed. Right now, the data has been good. The question is whether or not there's more to come in terms of the impact. He used it to argue for cuts, right? What's that? He used it to argue for cuts? No, he used it to argue for the Fed staying the same because remaining in place, not because of the potential inflationary impact.
23:34Our next guest recently addressed the issues playing out in the private credit space and so much more in a memo to clients detailing the developments. He says brought the credit sector to where it is today. Join us right now in an exclusive interview. It was Howard Marks, co-chairman of Oaktree Capital, which specializes in alternative investments, has$223 billion in assets under management. And you always, I think, are a calming force in the investing world. But help us understand. Let's go straight to the private credit issue. And then I want to get into so many other things. But given where we are and so many of the questions about what's happening in private credit, some of the gating issues that we're seeing, are you worried?
24:12Should we be worried? What should we actually be thinking about this? No investment medium is good or bad per se. It can be done well or poorly. It can be overdone or ignored. There's nothing wrong with lending money to companies. The question is, do you do it wisely? And my guess is that because so much money was available to people who would manage money in the space, some of them hoovered up too much, invested it too fast, and made some bad decisions. We'll find out. But the bedrock issue of lending money to companies, nothing wrong with that. I appreciate that. I think the question, therefore, is you have so many people who seem to be rushing for the exits and a number of these funds putting up gates.
24:56And that's what's supposed to happen, technically. But there's this question mark about whether, A, it should be happening and what it says about the larger product. Well, as you know from the period you explored in your book, often the wrong product gets sold to the wrong people. And so some people probably invested in private credit funds not understanding the limitations on liquidity. And then when they decided and they turned negative, they couldn't easily get out like they can in the stock market or a mutual fund. And they're shocked, like the guy in Casablanca who was shocked to find gambling in the bar.
25:36shocked to find out that their money wasn't available on daily on request. And this will always happen because things are sold to the wrong people. But that doesn't mean that the underlying product is wrong. And it's just that it has to be sorted out. What does it say about the valuations of, for example, a lot of the firms that live inside private equity portfolios? Because those have not been hit yet. Typically, by the way, for a credit fund to have a demonstrable problem, the equity needs to get wiped out first. Right. Well, when you hear the word private, the main distinction is that there is no market where these things are traded.
26:15So there's no market price to use as a reference point. And these things have to be valued by third parties, daily, weekly, monthly, whatever it is. And that's an imprecise product. And by the way, the job of the value is not clear. If you have a fund and I'm supposed to value the portfolio, am I supposed to value these things at what they're worth, what I could sell them for, what I could sell half for, what I could buy them at? Am I supposed to reflect the ups and downs of psychology or just the fundamentals? So the price is by definition wrong. And if people can get out of that price, other people in that fund may be benefited or hurt.
Read the full transcript
27:01In the public markets, we think of it as what you could get out at at any given moment, right? What someone would buy your shares for. What do you think the marks should be in terms of how you'd value private companies then? I think it's very hard to say. And by the way, it's not even true in the stock market because it's where you could sell one share. Right. But if you have a million shares, you may not be able to sell at that price. And yet everybody marks it at that price and there's no complaint. But, I mean, I think it should be valued at what an intelligent, unemotional buyer would pay for it today.
27:40For the entire business or for some percentage? Well, that's the question. And, well, I would say for the part of it we own. Howard, when you look at the market today, do you find a lot of bargains? Do you think it's expensive at this point? What's your. For the most part, Becky, this is not a market that's on sale. You know, every day there's a tug of war in the market between the optimist and the pessimist. The pessimist, the optimist had basically been winning for the last, I think now it's 43 months, roughly the 1st of October 22. The pessimist turned optimistic and they've basically won since then.
28:22There have been a couple of interruptions, weeks, months, even 22 was a bad year. But for the most part, the market's up and the stock market has more than doubled over that period. So there are very few bargains. Bargains come when people panic, want to get out and are willing to take an inadequate price. That doesn't describe today. Are you surprised by just how concentrated, though, the success in the market has been? Because so much of it does seem to be focused on AI. And if you really were to X that piece of it out, I don't know, maybe you would get to some attractive valuations. I don't know.
29:00Well, there's there's always there's often some group that commands the attention. And today it's AI and the Mag 7. I happen to I'm not active in the stock market. I'm not an expert on these companies. I happen to believe that the MAG7, most of or all of them are the best companies I've ever seen. And, you know, they're mostly selling at P.E. ratios in the 30s, price earnings ratios. That doesn't seem high to me. When I was a kid and came into this business in 69, the nifty 50 were selling at P.E. ratios between 60 and 90. So today's Mag 7 in the 30s seem reasonable. They sold soft drinks. That's right.
29:47Well, and my favorite, Joe, is simplicity patterns. They sold patterns by which women could make their own clothes. Not that great a business today. Doesn't seem like a growth business. In GE, as long as you had a couple of pennies in the drawer, pennies per share in the drawer every quarter, you were worth 50 times earnings. But today's companies, I mean, you know, you can't just look at P.E. ratios and know if it's high or low. And so, as I say, the P.E. ratios on the Mag 7 are not astronomical, in my opinion. And if you look at the companies, they're so much better qualitatively than the companies of the past.
30:28Now, one of the things we were talking about earlier this morning, and this is always a question like, is this time different? Dan Schulman from Verizon was talking about 25 to 30 percent unemployment. Within two to five years. Within two to five years as a function of all this technology. And whether you think that, I mean, if that's true, I don't think that's baked into these equity markets unless you think that there's some other mechanism that's going to change the redistribution of wealth and the like. Well, you know, I'm very worried about that, Andrew. I wrote a memo about AI in December and in a postscript on the social effects.
31:07I said, I'm very concerned that it could be catastrophic. Now, you talk to people in Silicon Valley, they're unworried. They'll say, oh, it's great. Nobody's going to have to work. Right. I think we get so much more from our work than just a paycheck. Right. And the government, in theory, can make up the paycheck, but they can make up the sense of purpose and the reason to get out of bed and the structure for your day. So I do worry about that. And look, the stock market's at an all-time high. Given that I think you focus on the psychology of markets and trading and how people think about all this, how do you think about prediction markets right now?
31:44Well, it's entertainment. You know, it's like any casino. It's not a fundamental bet. But there are hedge funds, apparently, that are using it on a daily basis. I don't think they think they're in the entertainment business. They think they think they're hedging their bets or doing something else. Well, I mean, they're concerned with a different part of the world than I am. I'm concerned with what I said earlier makes sense in the long run. They're dealing with daily and weekly and monthly performance. I don't know anything about that. But, you know, if you're talking about... I'm a football fan.
32:22I love to go to the games. I love to watch the game. I care who wins. I don't care whether the next play is a pass or a run. I don't care how many yards a certain runner is going to get. These are the things that don't matter. But, you know, in today's short attention span world, people aren't content to just sit in the stands and root for their home team. They have to make a bet every minute or so. And they like to see the odds play out on the screens, on the seat in front of them. These are not the things that matter. You don't win a championship because you've got the side bet right. Only who wins the game.
33:04You don't get rich betting on who's going to win. Do you think they should all be allowed, not allowed? That's a moral or political question. You know, we have gambling is legal in some states and not in others. uh uh gambling is probably harmless per se except that some people get addicted and get into big trouble uh but uh you know if you said to me uh is calci okay uh i'd say well yes as long as they you can only bet up to 10 bucks in terms of i'm going to actually just go back for just a moment on the private credit stuff but because i think it matters in so many other ways a lot of these kind of private credit like products, private equity products, venture capital products are going to be between the SEC and the Labor Department and others in our 401k plan soon.
33:53Right. And whether you think, I don't know if you think it's a moral or political question, whether you think those plans should be in 401k plans. A great eye opener. I went to visit one of my clients, a CEO, and he talked about the fact that his workers trade their 401ks sitting on the shop floor at lunch. Really? Yes. That's not a great idea. And we should all try to discourage people from viewing serious financial matters as entertainment. And people should have products that are right for them. But if you're going to get into a private equity fund or a private credit fund and then expect to be able to trade it, you're obviously making a miscalculation.
34:37If you want to get in and hold it for 30 years, probably not a bad idea. It's all the question of the suitability. That used to be a real big issue, and we should stick with that. It's an important consideration in providing financial services. Howard, you have a very calming demeanor. I think you look at this all pretty logically, and you try and strip the emotion out of it, I would guess. Is that part of your theory on this? Oh, absolutely. I mean, this is this is a serious matter. It should be taken seriously. And emotion is the enemy. It has to be overcome. Emotion, what we call human nature, tends to get us excited when things go well.
35:22And as things go well, prices, prices rise, rise, rise. And people want to buy more, more, more. And then as things go poorly, prices go down, down, down. People want to sell more. I don't know about you, Becky. I like to buy when things are on sale, not be coerced into selling when things are on sale. You want other people to be emotional, just not you. Because you won't be able to gauge anything. If everybody was like you, you wouldn't know what to do. Well, if nobody made mistakes, then you couldn't get more than a fair risk adjusted return, Joe, which is not our goal. But if you want to be a superior investor, your job can be reduced to, I want to take advantage of the mistakes that other people make.
36:04I want to be the buyer when people sell things too cheap. I want to be the seller when they buy too dear. For a very long time, the private markets were outperforming the public markets. But, you know, if you look at a lot of funds recently, with the exception of maybe some of the stuff that's in AI and the like, meaning Anthropic and OpenAI and SpaceX, it hasn't necessarily. I mean, some of the vintages more recently have actually underperformed. And I wonder whether we're now in this period of time where we're also talking about making these funds available to the public just at a time when they're not performing as well, how we're supposed to think about that.
36:41Well, first of all, I don't want to get too academic, but you used the word necessarily. You said they don't necessarily outperform. Nothing necessarily outperforms. Everything's going to have its day and then its time when it underperforms. These things rotate. I've spent a lot of time thinking about the biggest mistake that investors make. It is the belief that something can go up more than something else forever. because if it goes up more than something else long enough, it probably gets overvalued relative to that other thing. It becomes a bad idea. So the point is, you know, my favorite saying is that what the wise man does in the beginning, the fool does in the end.
37:25Buffett says it more colorfully, as always. First, the innovator, then the imitator, then the idiot. So where are we in that process right now? Well, it depends on with God to which. But I mean, there's been there's been what happens is that people pile in later. And again, your book illustrated this beautifully. That's why I love this so much. Thank you. They they are they they look on as others make money and they get jealous. Kindle Burger said in Mania's Panics and Creations, there is nothing so injurious to your mental well-being as to watch a friend get rich. and they look on and they see others get rich.
38:04They say, I wish that was me and I better get in. And if it goes up another day and I'm not in there, I'm going to have to kill myself. So they jump in, even though it's already up. And that's the that's the imitator or maybe the idiot. And, you know, you don't want to if the British have this saying, pass the parcel. You don't want to be the person who buys it last. You want to buy it first or early or maybe average. But you don't want to be the last buyer. And you remember the game of hot potato from when we were kids? Thank you for throwing the potato on the table this morning. OK. Appreciate it.
38:41Howard Marks. I hope that wasn't too ephemeral. No, that was wonderful. No, that was terrific. Thank you very much. Appreciate it. Next up on Squawk Pod, a conversation with former FDA commissioner Dr. Scott Gottlieb about innovation in medicine, cancer treatments three decades in the making, and therapeutic psychedelics spotlighted in an executive order, specifically ibogaine. That was something that veterans wanted a sort of rational development process around. In fact, if you look at the president's executive order, he referenced that compound specifically. We'll be right back.
39:21If you are hearing this, you have been chosen. Chosen by Hangry Joe's Hot Chicken. Welcome to your reprogramming. Relax and let the flavors wash over you. You are getting very, very hangry. Hangry for golden fried perfection. You are feeling warm all over. When you wake, you will understand a new reality of flavor. you will know. Hangry Joe's. Welcome to our flock. Hangry Joe's hot chicken and wings. If you know, you Joe. My mom inspired me to dream big and work hard. Siner Adams! What would you like the power to do? Bank of America. Proud to be the official bank of U.S. soccer and FIFA World Cup 2026.
40:05Bank of America N.A. Member FDSE. This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com slash marketupdatepodcast or find Schwab Market Update wherever you get your podcasts.
40:39This is Squawk Pod. Stand, Andrew, five, three, two, one, up in Andrew. Cue his mic. You're watching Squawk Box right here on CNBC. I'm Andrew Ross-Sorkin, along with Joe Kernan and Becky Quick. Let's bring in former FDA Commissioner Dr. Scott Gottlieb. He is a board member with Pfizer and Illumina. He's also a CNBC contributor. And Dr. Gottlieb, thank you for being here this morning. We took out the intro because there's so many things we want to get to today. First of all, we were talking earlier this morning about Eli Lilly nearing this deal for this cancer biotech company called Colonia. They have a CAR-T therapy for multiple myeloma.
41:15And I think we're interested basically in the CAR-T therapy, what this might mean, deal or no deal. Yeah, look, this is an in vivo CAR-T therapy. So what we're seeing now is companies start to invest in ways to modify T cells in the body, not to withdraw the T cells. If you look at the typical CAR-T therapies, the ones that were approved when I was at FDA, drugs like Kimria, those cells were extracted from the body. they're modified through genetic engineering in a laboratory and then re-infused into the patient. The vein-to-vein time, when you extract the cells, modify them, and then ship them back to the patient, that could be multiple weeks.
41:48And so it's an expensive process. It's a difficult process. You don't always get back a yield of cells that can be delivered as a therapy. And so what you're seeing now is technologies that allow these CAR T cells, these T cells to be modified inside the patient's body, either by administering a virus that will modify them genetically or a lipid nanoparticle that also does the same thing. So this could be very effective for certain conditions where you don't need complete suppression of B cells because the CAR T cells suppress B cells. So things like for cancer, you might want a very robust suppression of malignant B cells.
42:21But for diseases like autoimmune diseases, where a lot of these in vivo strategies are being used, this approach could be much better. And you've seen all these in vivo CAR T companies that have developed these technologies now get acquired by American pharmaceutical companies. So the industry has made a big bet on this technology. And that's a short amount of time because you approved the very first CAR-T therapy. Yeah, that was Kim Rhea. We approved the first three at the time. You've seen a lot of innovation in this space. And look, the results have been very good. The clinical results from these various trials have been very good in these various indications.
42:52The data right now in autoimmune disease looks very encouraging. The ability to sort of reset someone's autoimmune system for diseases like lupus. Some of these patients look like they're getting functional cures of intractable autoimmune diseases. Let's talk very quickly. Pancreatic cancer. There were a couple of things over the weekend that came up. This mRNA vaccine that shows lasting results in the early trials. Most of the patients who got this are still alive six years later. That's incredible. Yeah, these results look very good. Some of this data is coming out of Memorial Sloan Ketamine here in New York City.
43:20I wouldn't really call this a vaccine. What you're doing is you're administering an antigen that's derived from the patient's own tumor to effectively train the immune system. The same thing. This is similar to a CAR-2 therapy. Right. Well, it's similar to the in vivo CAR T strategies, too, because you're doing it in vivo inside the patient's body. And these are being administered in conjunction with immunotherapies. So what you're doing is you're training the patient's immune system to recognize their cancer. Then you're giving other drugs in combination with that that rev up the immune system.
43:49So now their immune system not only can see the cancer, but it's supercharged to be able to go out and attack it. Did you think when you were approving the first CAR T therapies that we would be here this far down the road? Yeah, I mean, certainly I didn't think about the mRNA strategies in this context. The mRNA technology is relatively new. The technology around cancer vaccines, what people call broadly cancer vaccines, ways to try to train the immune system to recognize cancer. We've been working on these for probably three decades now. I think the innovation that we're seeing right now is the mRNA approach seems to be a very good approach to try to individualize the immune response to particular patients.
44:26because cancer antigens and solid tumors are highly variable. And so they change from patient to patient. They also change over time. So you need some kind of approach that allows you to really personalize that. And these approaches do that. It's amazing. I'm thrilled to hear it. Let's get now to the president's executive order over the weekend. This was to approve or to go after psychedelics. It was based on something that Joe Rogan had sent him. What happened? What is this stuff? Yeah, so I don't know the background with respect to Joe Rogan. Look, there's been a lot of focus on psychedelics, various psychedelic drugs for the treatment of certain intractable mental health conditions.
45:02There's been some encouraging data. What the president did in the context of the executive order was try to basically expedite the development and the approval of these products once they show promising data. So the executive order, I think, was very well calibrated in terms of keeping this within the remit of FDA and really just trying to give an impetus to get these products to the market more quickly once they show safety and efficacy in phase three clinical trials. It also deals with FDA's relationship with DEA because one of the bottlenecks to getting controlled substances approved once they show convincing clinical data was the rescheduling process.
45:39DEA would have to go and reschedule these drugs. And so the president also gave a nudge to FDA and DEA working together. So I think it was a very sound policy. I think for patients, they're going to be pleased that FDA is now focusing more on this with the impetus of the executive order. I think for a lot of people who have been proponents of psychedelics, it could be unsatisfying insofar as I think what they want is these drugs to sit outside the traditional approval process. And I think that's been part of the appeal over time. And this puts it squarely within the approval process, but just makes that approval process more efficient.
46:12This is something that combat veterans and others in particular have been trying. Right. So a drug called Ibogaine, which some veterans are going to Mexico to get in clinics in sort of an unsupervised fashion. This carries certain risks associated with it, particularly cardiovascular risks that could be quite serious. You don't want people getting it outside a supervised medical setting. That was something that veterans wanted a sort of rational development process around. In fact, if you look at the president's executive order, he referenced that compound specifically. specifically. And so there's a lot of encouraging data, albeit in, you know, small series and anecdotal data.
46:46There's about six or seven pharmaceutical companies, biotech companies that are looking at these products. So I think you're seeing more activity. And I think this executive order is going to help that. One of the challenges to doing clinical trials here is you get functional unblinding. So basically, if you have a clinical trial, you have a placebo arm and an active arm getting a psychedelic drug, people know when they're tripping. So it's hard to blind the trial. And so development here has been difficult. I think FDA is going to have to think about some different strategies. They put out a guidance in 2023 to try to address this, and that has sort of instigated more development in the biotech community.
47:19I think what the president is going to put another tailwind behind that. You don't always know. I feel like I'm tripping here on certain days. Right now? No, not right now. A week ago or so. Why'd they pull this melanoma? I mean, there's nothing for it, really. Did they pull it again? They pull it again, right? Well, they didn't pull it. They asked for another letter, right? So it was, they got a complete response letter, so it didn't get approved. And then they re-reviewed it, and they issued another complete response letter. Look, I don't know the details of it. The data looked promising to me.
47:51It was a different way to attack the disease. There's a lot of good therapies right now for malignant melanoma, but this looked different in terms of what it was trying to do using an oncologic virus. And so I don't know why the FDA is skeptical of this. But this is the second time, right? And it gets immediately the journals all over McCary and the staff for not almost making the case that these are people that really need something. Why are you holding this up? Yeah, look, I think that's part of the story. I think also people argue that this company had a prior agreement with the FDA around the clinical trial that was done and that FDA reneged on that guidance that it had given.
48:29And that's basically the argument that you're seeing spill out publicly. I was going to say, that's not the only company that said that, though. No, there's a number of companies now, and this is why you see the reporting in the Wall Street Journal and the editorials. Companies feel that they've had agreements with the agency, and the agency changed its approval standards. And look, historically, you've seen this from time to time, where medical practices evolved in a way where the prior guidance that FDA gave no longer makes sense in the context of the treatments that are available. But I think you've seen sort of a series of these, and that's why there's a sense.
48:58Is that the case? Has medical development changed to the point that it doesn't make this prior guidance make sense at this point? Yeah, I don't think that was the—I wouldn't argue based on what I know, and I just know what's public. I wouldn't argue that's true in this case, because the sort of progress we've seen in malignant melanoma was apparent years ago, a couple of years ago when this guidance was given, and really hasn't changed. I mean, it's improved, but it hasn't proved so dramatically that you would say this is no longer a relevant product. So I don't know if that's true in this case.
49:29And I'm speaking more broadly, too. That seems to be the case with several of these companies who have said, we thought we had an understanding with the FDA. I'm not sure the medicine, the medical discovery process has changed that. No, I think in a lot of these cases, these anecdotal cases where you see the FDA, the argument is that they've changed their guidance. It really isn't against the backdrop of any dramatic change in clinical practice. And so it begs the question, why has the FDA shifted? Dr. Gottlieb, thank you. We love being able to ask you all the questions that bubble up in our heads.
50:00Glad I can answer them. Yeah, exactly. And we appreciate having you here. Thanks a lot. Good to see you. You made it. That is Squawk Pod for today. It was a long one, chock full of news. We thank you for listening today and every day that you do. Squawk Box is hosted by Joe Kernan, Becky Quick, and Andrew Ross Sorkin. Tune in weekday mornings on CNBC at 6 Eastern. or get the best of our TV show right into your ears when you follow Squawk Pod wherever you get your podcasts. We'll meet you right back here tomorrow. We are clear. Thanks, guys. Thank you so much.
50:53Daily Market Preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com slash market update podcast, or find Schwab Market Update wherever you get your podcasts.
From the publisher
As concerns mount regarding the health of the private credit ecosystem, Oaktree Capital Management co-chairman Howard Marks offers perspective–and some investing advice–when it comes to private lending. Former FDA Commissioner Dr. Scott Gottlieb discusses Eli Lilly’s deal to expand its cancer treatment pipeline as well as President Trump’s executive order on therapeutic psychedelics. Plus, Kevin Warsh’s Fed Chair nomination hearing is this week, and Anthropic’s Mythos is at work within the NSA, despite being blacklisted by the US government.
Steve Liesman 14:36
Howard Marks 23:54
Dr. Scott Gottlieb 41:27
In this episode:
Steve Liesman, @steveliesman
Andrew Ross Sorkin, @andrewrsorkin
Becky Quick, @BeckyQuick
Joe Kernen, @JoeSquawk
Katie Kramer,
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

